춘계학술대회 : 일반포스터 ; Kikuchi병(조직구성 괴사성 림프선염) 1예

권현조,이우선,김미연,박영민,김형옥 대한피부과학회 2006 초록집 Vol.44 No.10

Gastric neurofibroma in von Recklinghausen disease : a cause of upper gastrointestinal bleeding

권보상,심정옥,서정기,양혜란,고재성,정성은,김우선,강경훈 대한소아청소년과학회 2006 Clinical and Experimental Pediatrics (CEP) Vol.49 No.2

Neurofibromatosis type 1 (von Recklinghausen disease, NF1) involves the central and peripheral nervous systems as well as the skin, bone, endocrine, gastrointestinal and vascular systems. The gastrointestinal neurofibroma associated with NF1 has been infrequently reported. We report our experience with a 15-year-old boy who had a gastric plexiform neurofibroma with upper gastrointestinal bleeding and underwent a tumorectomy because of massive upper gastrointestinal bleeding. We conclude that gastrointestinal bleeding and anemia in the setting of NF1 mandates complete endoscopic examination of the digestive tract to rule out neurofibromas. Surgical resection is the standard treatment. 위장관계의 신경섬유종의 발생빈도는 드물다고 알려져 있다. 저자들은 제1형 신경섬유종증의 15세 남자 환아에서 상부위장관 출혈로 발현한 위에 생기는 신경섬유종을 내시경 및 상부위장관조영술을 통해 진단을 내리고, 수술적 제거를 시행하였던 1례를 경험하였기에 문헌 고찰과 함께 보고하는 바이다.

조기 위암 환자에서 전이암과 감별이 필요했던 간내 단발성 괴사성 결절: 3T MRI 및 PET/CT 소견

최우선,김기현,이화연,이종범,권귀영 대한자기공명의과학회 2009 Investigative Magnetic Resonance Imaging Vol.13 No.2

Solitary necrotic nodule (SNN) of the liver is a very uncommon benign lesion, and it is detected incidentally as a rule. It is important to differentiate SNN radiologically from various single hepatic nodules because SNN mimics hepatic metastasis, especially in staging work up of known primary malignancy. The reported imaging findings of SNN are well-defined nodule without enhancement or with subtle peripheral enhancement. There has been no report about the target-like SNN of the liver and about the imaging finding of 3T magnetic resonance imaging and positron emission tomography. We report a case of targetlike SNN of the liver, mimicking hepatic metastasis, with findings of various imaging modalities and try to find a cause of this nodule according to the pathologic and literature review. 간에 생기는 단발성 괴사성 결절은 매우 드문 양성 질환으로 대개 아무 증상 없이 우연히 발견되고, 간에서 생길 수 있는 여러 가지 단발성 병변과의 감별을 필요로 하며, 특히 악성 종양의 병기 결정에 있어서 간내 전이암과 구별하는 것은 매우 중요하다고 알려져 있다. 영상의학적으로 간의 단발성 괴사성 결절은 조영증강이 없거나 미약한 주변부 조영증강을 보이는 경계가 좋은 간내 결절로 보고되고 있다. 하지만 단발성 괴사성 결절이 영상에서 과녁 모양으로 보이는 경우는 지금까지 보고된 바 없으며, 특히 고자장의 자기 공명 영상과 양성자 방출 단층 촬영 소견이 보 고된 경우도 전무하다. 이에 저자들은 조기 위암 환자에서 과녁 모양으로 보여 전이암과 감별이 어려웠던 간내 단발성 결절을 경험하여 이의 다양한 영상 소견을 보고하고자 하며, 병리학적 소견과 이에 대한 문헌 고찰을 통해 원인을 알아 보고자 하였다.

직교배열표를 이용한 이산설계 공간에서의 Steering System 설계

권우성(Woosung Kwon),박우선(Woosun Park),김동석(Dongseok Kim) 한국자동차공학회 2004 한국자동차공학회 춘 추계 학술대회 논문집 Vol.- No.-

The design of experiment (DOE) with orthogonal arrays is adopted when the engineering design is needed in a discrete design space. In this research, a design process with orthogonal array is performed to obtain the optimum design which satisfy the frequency target of the steering system. The optimum design is determined from the analysis of means (ANOH) and sensitivity information about design variables is evaluated by the analysis of variance (ANOVA). Interactions between design variables are investigated to achieve additivity which should be valid in using orthogonal array. It is shown that when strong interactions exist, the DOE process with orthogonal array considering interaction is introduced to find out optimum design .

Molecular subtyping in outcome of AGC

이기쁨,권우선,박세정,정현철,라선영 대한내과학회 2018 대한내과학회 추계학술대회 Vol.2018 No.1

Identification of Natural Products as Novel PI3Kβ Inhibitors Through Pharmacophore-based Virtual Screening

Xuemei Jin,권우선,김태수,허정녕,정현철,최지원,노경태 대한화학회 2018 Bulletin of the Korean Chemical Society Vol.39 No.3

Phosphatidylinositol 3-kinase beta (PI3Kβ) is the dominant isoform of PI3K and has been implicated in thrombosis as well as phosphatase and tensin homologue-loss-induced tumorigenesis. PI3Kβ has been considered to be an attractive target for anticancer drug discovery, and several PI3Kβ inhibitors have progressed into clinical trials. Here, we disclose the discovery of two natural products (PBY-0002 and PBY-0006) that have inhibitory effects on PI3Kβ. These two natural products were identified through pharmacophore-based virtual screening, molecular docking, and a molecular dynamics simulation. Furthermore, an in vitro assay against human gastric cancer cell lines revealed that these two compounds showed anticancer activity. To identify the binding modes of PBY-0002 and PBY-0006 further, we performed a systematical investigation with comparison to the binding mode of GSK2636711, which is a known PI3Kβ inhibitor. The results demonstrated that PBY-0002 and PBY-0006 were tightly embedded into the ATP-binding site via hydrogen bonds and π-cation interactions. These two natural products can provide a promising starting point for the rational design of potent analogs with inhibitory activity against PI3Kβ.

기관지경 검사 동영장 교육자료 개발 및 검사 이해증진

오명순,김경옥,장춘미,고은,우선경,박혜영,우경희,권이슬 한국의료QA학회 2008 가을학술대회 Vol.2008 No.3

Circulating tumor cell as a surrogate biomarker in advanced gastric cancer with bone marrow invasion

김문현,이가든,이기쁨,권우선,정현철,라선영 대한내과학회 2019 대한내과학회 추계학술대회 Vol.2019 No.1

Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy

정연준,라선영,정승현,이충근,권우선,윤수진,정민규,김효송,정현철 연세대학교의과대학 2023 Yonsei medical journal Vol.64 No.9

Purpose: For precision medicine, exploration and monitoring of molecular biomarkers are essential. However, in advanced gas tric cancer (GC) with visceral lesions, an invasive procedure cannot be performed repeatedly for the follow-up of molecular bio markers. Materials and Methods: To verify the clinical implication of serial liquid biopsies targeting circulating tumor DNA (ctDNA) on treatment response, we conducted targeted deep sequencing for serially collected ctDNA of 15 HER2-positive metastatic GC pa tients treated with anti-PD-1 inhibitor in combination with standard systemic treatment. Results: In the baseline ctDNAs, 14 patients (93%) harbored more than one genetic alteration. A number of mutations in well known cancer-related genes, such as KRAS and PIK3CA, were identified. Copy number alterations were identified in eight GCs (53.3%), and amplification of the ERBB2 gene (6/15, 40.0%) was the most recurrent. When we calculated the mean variant allele frequency (VAF) of mutations in each ctDNA as the molecular tumor burden index (mTBI), the mTBI trend was largely consistent with the VAF profiles in both responder and non-responder groups. Notably, in the longitudinal analysis of ctDNA, mTBI provided 2–42 weeks (mean 13.4 weeks) lead time in the detection of disease progression compared to conventional follow-up with CT im aging. Conclusion: Our data indicate that the serial genetic alteration profiling of ctDNA is feasible to predict treatment response in HER2-positive GC patients in a minimally invasive manner. Practically, ctDNA profiles are useful not only for the molecular diag nosis of GC but also for the selection of GC patients with poor prognosis for systemic treatment (ClinicalTrials.gov identifier: NCT02901301).

First-in-Human Phase 1 Study of a B Cell– and Monocyte-Based Immunotherapeutic Vaccine against HER2-Positive Advanced Gastric Cancer

정민규,이기쁨,김효송,권우선,김현옥,김신영,박명환,김우현,최기영,오태권,강창율,정현철,라선영 대한암학회 2024 Cancer Research and Treatment Vol.56 No.1

Purpose BVAC-B is an autologous B cell– and monocyte-based immunotherapeutic vaccine that contains cells transfected with a recombinant human epidermal growth factor receptor 2 (<i>HER2</i>) gene and loaded with the natural killer T cell ligand alpha-galactosylceramide. Here, we report the first BVAC-B study in patients with HER2-positive advanced gastric cancer.Materials and Methods Patients with advanced gastric cancer refractory to standard treatment with HER2+ immunohistochemistry ≥ 1 were eligible for treatment. Patients were administered low (2.5×10⁷ cells/dose), medium (5.0×10⁷ cells/dose), or high dose (1.0×10⁸ cells/dose) of BVAC-B intravenously four times every 4 weeks. Primary endpoints included safety and maximum tolerated BVAC-B dose. Secondary endpoints included preliminary clinical efficacy and BVAC-B-induced immune responses.Results Eight patients were treated with BVAC-B at low (n=1), medium (n=1), and high doses (n=6). No dose-limiting toxicity was observed, while treatment-related adverse events (TRAEs) were observed in patients treated with medium and high doses. The most common TRAEs were grade 1 (n=2) and grade 2 (n=2) fever. Out of the six patients treated with high-dose BVAC-B, three had stable disease with no response. Interferon gamma, tumor necrosis factor-α, and interleukin-6 increased after BVAC-B treatment in all patients with medium and high dose, and HER2-specific antibody was detected in some patients.Conclusion BVAC-B monotherapy had a safe toxicity profile with limited clinical activity; however, it activated immune cells in heavily pretreated patients with HER2-positive gastric cancer. Earlier treatment with BVAC-B and combination therapy is warranted for evaluation of clinical efficacy. Purpose BVAC-B is an autologous B cell– and monocyte-based immunotherapeutic vaccine that contains cells transfected with a recombinant human epidermal growth factor receptor 2 (HER2) gene and loaded with the natural killer T cell ligand alpha-galactosylceramide. Here, we report the first BVAC-B study in patients with HER2-positive advanced gastric cancer. Materials and Methods Patients with advanced gastric cancer refractory to standard treatment with HER2+ immunohistochemistry ≥ 1 were eligible for treatment. Patients were administered low (2.5×107 cells/dose), medium (5.0×107 cells/dose), or high dose (1.0×108 cells/dose) of BVAC-B intravenously four times every 4 weeks. Primary endpoints included safety and maximum tolerated BVAC-B dose. Secondary endpoints included preliminary clinical efficacy and BVAC-B-induced immune responses. Results Eight patients were treated with BVAC-B at low (n=1), medium (n=1), and high doses (n=6). No dose-limiting toxicity was observed, while treatment-related adverse events (TRAEs) were observed in patients treated with medium and high doses. The most common TRAEs were grade 1 (n=2) and grade 2 (n=2) fever. Out of the six patients treated with high-dose BVAC-B, three had stable disease with no response. Interferon gamma, tumor necrosis factor-α, and interleukin-6 increased after BVAC-B treatment in all patients with medium and high dose, and HER2-specific antibody was detected in some patients. Conclusion BVAC-B monotherapy had a safe toxicity profile with limited clinical activity; however, it activated immune cells in heavily pretreated patients with HER2-positive gastric cancer. Earlier treatment with BVAC-B and combination therapy is warranted for evaluation of clinical efficacy.